Atria Investments’s Ionis Pharmaceuticals IONS Stock Holding History

Atria Investments’s Portfolio IONS Stock Details IONS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$372K	Sell	4,690 -537	-10%	-$40.4K	﹤0.01%	1702
2026 Q1	$392K	Sell	5,227 -428	-8%	-$33.8K	﹤0.01%	1582
2025 Q4	$447K	Sell	5,655 -1,375	-20%	-$104K	0.01%	1514
2025 Q3	$460K	Sell	7,030 -1,156	-14%	-$56.4K	0.01%	1466
2025 Q2	$323K	Buy	+8,186	New	+$268K	﹤0.01%	1678
2020 Q1	–	Sell	-7,233	Closed	-$437K	–	859
2019 Q4	$437K	Buy	7,233 +3,545	+96%	+$211K	0.01%	835
2019 Q3	$221K	Sell	3,688 -1,092	-23%	-$71.2K	0.01%	813
2019 Q2	$320K	Sell	4,780 -1,852	-28%	-$131K	0.01%	719
2019 Q1	$538K	Sell	6,632 -961	-13%	-$62K	0.02%	515
2018 Q4	$410K	Buy	7,593 +522	+7%	+$26.6K	0.02%	566
2018 Q3	$365K	Buy	+7,071	New	+$332K	0.01%	696

Other funds holding IONS

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Atria Investments's IONS Position: Q2 2026 in Review

Atria Investments reduced its Ionis Pharmaceuticals (IONS) stake by 10% in Q2 2026, selling an estimated $40.4K and leaving 4,690 shares worth $372K. The position accounts for ﹤0.01% of the portfolio, ranked #1702.

Atria Investments first reported a position in IONS in Q3 2018 and has held it in 11 quarters since. The position peaked at $538K in Q1 2019. 515 funds tracked by Wall St. Rank hold IONS as of Q2 2026.

Atria Investments held 4,690 shares of Ionis Pharmaceuticals worth $372K as of Q2 2026.
Atria Investments sold 537 Ionis Pharmaceuticals shares in Q2 2026, an estimated $40.4K.
Ionis Pharmaceuticals made up ﹤0.01% of Atria Investments's portfolio in Q2 2026, its #1702 holding.
Atria Investments first reported a position in Ionis Pharmaceuticals in Q3 2018 and has held it in 11 quarters since.
Atria Investments's Ionis Pharmaceuticals position peaked at $538K in Q1 2019.
515 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q2 2026.

Based on Atria Investments's 13F filing for Q2 2026, filed 28 Jul 2026.